Caroline Seymour

Ruta D. Rao, MD, elaborates on the findings of the ABCSG-16, SOFT, and TEXT clinical trials and how they have shaped adjuvant treatment for ER-positive breast cancer.

Andrew Ko, MD, discusses how the approval of pembrolizumab has impacted patients with positive PD-L1 expression and how clinical trials that have reshaped the standard of care in patients with gastric and GEJ cancers.

R. Kate Kelley, MD, discusses the incidence of and risk factors for HCC, and emphasizes the sequence of clinical trials that characterized the field in 2017.

Benny Weksler, MD, FACS, discusses the use of surgery in a biomarker-driven and drug-dependent era and highlights other cases in which surgery can benefit patients with NSCLC.

Katherine Van Loon, MD, MPH, discusses the emerging use of neoadjuvant therapy and nonoperative approaches for patients with locally advanced rectal cancer.

Margaret A. Tempero, MD, discusseds frontline treatment options in pancreatic cancer and emphasized the use and difficulties of conventional and incoming therapies across disease states.

Amit Gupta, MD, discusses the superiority of robotic cystectomy compared with open cystectomies and its relevance in the current treatment landscape of bladder cancer.

Lori Ann Leslie, MD, provides expert insight on the latest developments in the field of follicular lymphoma.

Andre Goy, MD, discusses the evolution of MCL treatment, specifically the integration of new agents in both the frontline and relapsed/refractory settings, and the importance of MRD status and maintenance therapies.

Noa Biran, MD, discusses treatment breakthroughs and emerging advances in the field of multiple myeloma.

Edouard J. Trabulsi, MD, discusses emerging multimodal treatment approaches for patients with locally advanced prostate cancer.

Jason M. Long, MD, discusses the latest developments with minimally invasive surgical approaches in the treatment of patients with non–small cell lung cancer (NSCLC).

M. Patricia Rivera, MD, discusses the potential of lung cancer screening, challenges in its adoption, and methods to enhance its efficacy.

Chloe E. Atreya, MD, PhD, discusses the latest treatment advances in mCRC, including tumor sidedness and emerging immunotherapy strategies.

Tiffany A. Traina, MD, discussed the potential for PARP inhibitors, as well as immunotherapy and antibody-drug conjugates, for the treatment of patients with triple-negative breast cancer.

Eric A. Collisson, MD, discusses ongoing efforts to advance precision medicine in GI malignancies to improve the standard of care.

Howard M. Sandler, MD, discusses the emergence of hypofractionation as a viable treatment approach for patients with prostate cancer.

Parminder Singh, MD, discusses the potential of immunotherapy, the importance of sequencing to avoid disease progression, and the use of chemotherapy and radiation therapy to reach an unmet need in muscle-invasive bladder cancer.

Timothy J. Daskivich, MD, discusses the use of High-intensity focused ultrasound and other treatment strategies in the prostate cancer armamentarium.

Holger L. Gieschen, MD, discusses the latest developments with radiation therapy in non-small cell lung cancer.

James Wysock, MD, discusses the evolution of cytoreductive nephrectomy in renal cell carcinoma.

Edwin M. Posadas, MD, discusses the evolution of prostate cancer therapy, including the earlier use of advanced-stage agents and the potential for immunotherapy in the field.

David C. Portnoy, MD, discusses emerging developments with targeted agents in lung cancer.

Robert A. Figlin, MD, discusses the expanding RCC armamentarium and balancing the benefits and risks of standard and emerging treatments to achieve optimal outcomes.

Nichon L. Grupka, MD, discusses advances in hematopathology, specifically mutations as prognostic indicators, disease-associated versus disease-causing mutations, and advice for physicians who are working to navigate the field.

Alan H. Bryce, MD, discusses emerging agents and next steps in the treatment of patients with in nonmetastatic prostate cancer.

Alexander Perl, MD, discusses the implementation of CAR T-cell therapy in ALL and other advances with this unique treatment across the spectrum of hematologic malignancies.

William Donnellan, MD, discusses recent FDA approvals for the treatment of patients with AML and ALL, and highlighted emerging agents in the pipeline.

Benjamin P. Levy, MD, highlights trials that continue to shape the treatment landscape for patients with lung cancer.

Shirley Michelle Shiller, DO, discusses the application of biomarkers and the importance of educating practitioners on treatment advancements in NSCLC.